Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 5/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 2/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | NQO2 | P16083 | 7/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL144288 | 0.86 | GAA (0.53) | CFTRABL1KDM4EALDH1A1GAA | |
| SCHEMBL1884944 | 0.85 | GAA (0.64) | CFTRABL1KDM4EALDH1A1GAA | |
| SCHEMBL21857249 | 0.85 | GAA (0.50) | CFTRABL1KDM4EALDH1A1GAA | |
| SCHEMBL2849661 | 0.84 | CFTR (0.45) | CFTRABL1ALDH1A1GAAMAPT | |
| SCHEMBL7762378 | 0.84 | ABL1 (0.61) | CFTRABL1KDM4EALDH1A1GAA | |
| SCHEMBL28922445 | 0.84 | CFTR (0.66) | CFTRABL1KDM4EALDH1A1GAA | |
| SCHEMBL17030839 | 0.81 | ABL1 (0.57) | CFTRABL1KDM4EALDH1A1GAA | |
| SCHEMBL12488367 | 0.81 | CFTR (0.43) | CFTRABL1KDM4EALDH1A1GAA | |
| SCHEMBL11922587 | 0.81 | ABL1 (0.57) | CFTRABL1KDM4EALDH1A1GAA | |
| SCHEMBL12021191 | 0.81 | CFTR (0.62) | CFTRABL1KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-02-25 | — | — | US | disclosed |
| US-12162893-B2 | Tricyclic pyridones and pyrimidones | ERASCA, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-10-24 | — | — | US | disclosed |
| CN-118076612-A | Sulfur-containing heteroaromatic tricyclic KRAS inhibitors | 医睿世康药业研发公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4347603-A1 | SULFUR-CONTAINING HETEROAROMATIC TRICYCLIC KRAS INHIBITORS | Erasca, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-02-08 | — | — | US | disclosed |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-11845761-B2 | Tricyclic pyridones and pyrimidones | ERASCA, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-6150522-A | Antagonists of gonadotropin releasing hormone | MERCK & CO., INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6150352-A | ARYLQUINOLONE ANALOGS | MERCK & CO., INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6147088-A | USEFUL FOR THE TREATMENT OF A VARIETY OF SEX-HORMONE RELATED CONDITIONS | MERCK & CO., INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0901471-A4 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0920319-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (US) | 1999-06-09 | — | — | EP | disclosed |
| EP-0901471-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0901489-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997044041-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| WO-1997044339-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| WO-1997044321-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | CFTR 326/4885ABL1 67/4885KDM4E 2534/4885 |
| US-11845761-B2 | Tricyclic pyridones and pyrimidones | KRAS, NRAS, HRAS | CFTR 1205/4885ABL1 111/4885KDM4E 2592/4885 |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | CFTR 697/4885ABL1 82/4885KDM4E 3221/4885 |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CFTR 697/4885ABL1 82/4885KDM4E 3221/4885 |
| US-12162893-B2 | Tricyclic pyridones and pyrimidones | DHFR, TYMS, TYMP | CFTR 1960/4885ABL1 147/4885KDM4E 3415/4885 |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CFTR 524/4885ABL1 216/4885KDM4E 3220/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CFTR 524/4885ABL1 216/4885KDM4E 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.